Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Current Assets (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Current Assets data on record, last reported at $401.8 million in Q3 2025.

  • For Q3 2025, Current Assets rose 59.95% year-over-year to $401.8 million; the TTM value through Sep 2025 reached $401.8 million, up 59.95%, while the annual FY2024 figure was $377.4 million, 59.79% up from the prior year.
  • Current Assets reached $401.8 million in Q3 2025 per GLUE's latest filing, up from $299.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $401.8 million in Q3 2025 and bottomed at $182.9 million in Q3 2023.
  • Average Current Assets over 3 years is $273.4 million, with a median of $251.2 million recorded in 2024.
  • Peak YoY movement for Current Assets: dropped 17.26% in 2024, then surged 66.94% in 2025.
  • A 3-year view of Current Assets shows it stood at $236.2 million in 2023, then skyrocketed by 59.79% to $377.4 million in 2024, then increased by 6.46% to $401.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $401.8 million in Q3 2025, $299.5 million in Q2 2025, and $332.3 million in Q1 2025.